Molnupiravir for treating COVID-19

Molnupiravir (Lagevrio) is available on the NHS. It is a possible treatment for mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test, if:

• they have any risk factors that make it more likely to develop severe COVID-19 and
• both nirmatrelvir plus ritonavir and sotrovimab are not suitable.

Risk factors for developing severe COVID-19 are listed in section 5 of NICE’s technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on making decisions about your care.

Questions to think about

• How well does it work compared with other treatments?
• What are the risks or side effects? How likely are they?
• How will the treatment affect my day-to-day life?
• What happens if the treatment does not work?
• What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The NHS webpage on COVID-19 may be a good place to find out more.

These organisations can give you advice and support:

• Clinically Vulnerable Families, message: clinicallyvulnerable.org/contact
• Kidney Research UK, 0300 303 1100

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6936-4